Cargando…
The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
BACKGROUND: Transarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554637/ https://www.ncbi.nlm.nih.gov/pubmed/36248997 http://dx.doi.org/10.3389/fonc.2022.1005571 |
_version_ | 1784806743734222848 |
---|---|
author | Chien, Tzu-Ping Huang, Song-Fong Chan, Wen-Hui Pan, Kuang-Tse Yu, Ming-Chin Lee, Wei-Chen Tsai, Hsin-I Lin, Po-Ting Chen, Hsing-Yu Chen, Jui-Hsuan Lee, Chao-Wei |
author_facet | Chien, Tzu-Ping Huang, Song-Fong Chan, Wen-Hui Pan, Kuang-Tse Yu, Ming-Chin Lee, Wei-Chen Tsai, Hsin-I Lin, Po-Ting Chen, Hsing-Yu Chen, Jui-Hsuan Lee, Chao-Wei |
author_sort | Chien, Tzu-Ping |
collection | PubMed |
description | BACKGROUND: Transarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sarcopenia. MATERIALS AND METHODS: We retrospectively analyzed 260 HCC patients who received TACE between 2010 and 2015. Total psoas muscle was measured on a cross-sectional CT image before the first TACE session. Sarcopenia was defined by the pre-determined sex-specific cutoff value. We assessed the impact of sarcopenia and other biochemical factors on the overall survival and compared the new scoring system with other prognostic scoring systems. RESULTS: One hundred and thirty patients (50%) were classified as sarcopenia before the first TACE. They were older with a higher male tendency and a significantly lower body mass index (BMI). Cox regression multivariate analysis demonstrated that sarcopenia, multiple tumors, maximal tumor diameter≥ 5cm, major venous thrombosis, sarcopenia, AFP ≥ 200 ng/ml, and albumin<3.5mg/dL were independent poor prognostic factors for overall survival in HCC patients receiving TACE. Our scoring system comprising these factors outperformed other major scoring systems in terms of predicting survival after TACE. CONCLUSION: The current study demonstrated that sarcopenia was an independent prognostic factor for HCC undergoing TACE therapy. Our newly developed scoring system could effectively predict patient survival after TACE. Physicians could, based on the current score model, carefully select candidate patients for TACE treatment in order to optimize their survival. Further studies are warranted to validate our findings. |
format | Online Article Text |
id | pubmed-9554637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95546372022-10-13 The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization Chien, Tzu-Ping Huang, Song-Fong Chan, Wen-Hui Pan, Kuang-Tse Yu, Ming-Chin Lee, Wei-Chen Tsai, Hsin-I Lin, Po-Ting Chen, Hsing-Yu Chen, Jui-Hsuan Lee, Chao-Wei Front Oncol Oncology BACKGROUND: Transarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. We investigated the role of sarcopenia on overall survival in HCC patients receiving TACE and proposed a new prognostic scoring system incorporating sarcopenia. MATERIALS AND METHODS: We retrospectively analyzed 260 HCC patients who received TACE between 2010 and 2015. Total psoas muscle was measured on a cross-sectional CT image before the first TACE session. Sarcopenia was defined by the pre-determined sex-specific cutoff value. We assessed the impact of sarcopenia and other biochemical factors on the overall survival and compared the new scoring system with other prognostic scoring systems. RESULTS: One hundred and thirty patients (50%) were classified as sarcopenia before the first TACE. They were older with a higher male tendency and a significantly lower body mass index (BMI). Cox regression multivariate analysis demonstrated that sarcopenia, multiple tumors, maximal tumor diameter≥ 5cm, major venous thrombosis, sarcopenia, AFP ≥ 200 ng/ml, and albumin<3.5mg/dL were independent poor prognostic factors for overall survival in HCC patients receiving TACE. Our scoring system comprising these factors outperformed other major scoring systems in terms of predicting survival after TACE. CONCLUSION: The current study demonstrated that sarcopenia was an independent prognostic factor for HCC undergoing TACE therapy. Our newly developed scoring system could effectively predict patient survival after TACE. Physicians could, based on the current score model, carefully select candidate patients for TACE treatment in order to optimize their survival. Further studies are warranted to validate our findings. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9554637/ /pubmed/36248997 http://dx.doi.org/10.3389/fonc.2022.1005571 Text en Copyright © 2022 Chien, Huang, Chan, Pan, Yu, Lee, Tsai, Lin, Chen, Chen and Lee https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chien, Tzu-Ping Huang, Song-Fong Chan, Wen-Hui Pan, Kuang-Tse Yu, Ming-Chin Lee, Wei-Chen Tsai, Hsin-I Lin, Po-Ting Chen, Hsing-Yu Chen, Jui-Hsuan Lee, Chao-Wei The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title_full | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title_fullStr | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title_full_unstemmed | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title_short | The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
title_sort | combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554637/ https://www.ncbi.nlm.nih.gov/pubmed/36248997 http://dx.doi.org/10.3389/fonc.2022.1005571 |
work_keys_str_mv | AT chientzuping thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT huangsongfong thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chanwenhui thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT pankuangtse thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT yumingchin thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT leeweichen thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT tsaihsini thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT linpoting thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chenhsingyu thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chenjuihsuan thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT leechaowei thecombinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chientzuping combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT huangsongfong combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chanwenhui combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT pankuangtse combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT yumingchin combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT leeweichen combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT tsaihsini combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT linpoting combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chenhsingyu combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT chenjuihsuan combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization AT leechaowei combinationofsarcopeniaandbiochemicalfactorscanpredictthesurvivalofhepatocellularcarcinomapatientsreceivingtransarterialchemoembolization |